C Programming, C++, Cloud computing, Data science techniques, Java Programming, Machine learning techniques, MATLAB Programming, Python Programming, PyTorch, R Programming, Scala Programming, SQL, TensorFlow
This individual will serve as the quantitative systems pharmacology (QSP) lead on pre-clinical and clinical development programs providing pharmacology support and execution of clinical development plans that include characterization and prediction of pharmacokinetics and pharmacodynamics of the drug candidate. You will also work in close collaboration with scientists in Preclinical Development, Translational Research and Clinical Development to conduct quantitative PK/PD/safety/efficacy analyses for integration into overall program strategies. You will be responsible for all aspects of quantitative systems modelling & simulation strategies for candidate drug products from early development (pre-IND) through late stage development using model-based approaches to improve the efficiency of drug development, improve our mechanistic understanding of targeted pathways and exposure-response relationship of drug candidates. You will assist in providing mechanistic modelling rationale for dose regimen selection in first in human (FIH) trials and beyond, and identification of circumstances where dose adjustment or patient selection/stratification should be considered.
This is an exciting opportunity to be part of a passionate, high profile, high-impact Pharmacology team, and work in a highly dynamic and collaborative setting.
The level of the role will be commensurate with the individual’s level of experience.
Responsibilities:
Requirements:
Genmab will offer the successful application a challenging position, where the right candidate will have the opportunity to work with highly specialised people across functions in an informal, multicultural environment, with an aim to make a difference in the lives of people with cancer.
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schonharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan.
Princeton, NJ, USA
2-4 year
Utrecht, Netherlands
2-4 year
Utrecht, Netherlands
6-8 year
Copenhagen, Denmark
6-8 year
Princeton, NJ, USA
6-8 year
Princeton, NJ, USA
6-8 year
Copenhagen, Denmark
6-8 year
Utrecht, Netherlands
6-8 year
Copenhagen, Denmark
6-8 year
Utrecht, Netherlands
6-8 year
Princeton, NJ, USA
6-8 year
Utrecht, Netherlands
6-8 year
Copenhagen, Denmark
6-8 year
Copenhagen, Denmark
6-8 year
Utrecht, Netherlands
6-8 year